NuVasive CEO: No Sign Of Economic Hit To Spinal Devices

By · June 11, 2009 · 8 Comments
Uncategorized ·

NuVasive Inc. (NUVA) isn’t seeing the recession take a negative toll on the market for its spinal devices, the company’s top official said Wednesday.

Elsewhere in orthopedics, growth in the $11 billion market for replacement hips and knees has eased due to patients deferring procedures due to lost health insurance or worries about long breaks from work. But NuVasive, a small but fast-growing player in the $8 billion spinal market,

Posted By

Josh Sandberg has been recruiting specifically in the musculoskeletal industry for over 8 years. Throughout this time, he has been able to have a positive impact on his client’s businesses. With an educational background in Business Management, Josh is adept to discern which people will be the best fit for the company he is searching for by understanding how candidates will incorporate with the company’s culture and operational nuances. His experience as an executive in a start-up business has granted him the ability to understand what is takes to thrive in a hands–on environment, where desire and dedication are paramount for success.
  • Anonymous

    It is interesting to know that people are lining up for spine surgery. I guess if Lukianov said it, it must be true. Contrary to what he is hearing, distributors are saying that surgeons on the East Coast are reporting less demand for spine surgery. But it's summer time and kids are out of school and who wouldn't want to go on vacation rather than have some surgeon filet you open?

    A question for the analyst, why would you forecast such poor growth for the industry when on average the industry has grown 18-20% per year? As far as NuVasive growing 35%, maybe you should forecast 65%. Sounds like someone is trying to sell us futures.

  • GlobalMed

    It is great that Nuvasive is growing in these economic times. They do have some good, novel products in there portfolio and pipeline, but they also have plenty of cash for marketing and advertising.

    In the article, he states "I think what we're seeing from the surgeons is that there's absolutely no drop off whatsoever". He probably asked their advisory board, which would consist of the most prominent surgeons in the field. The top notch surgeons are probably not seeing any dropoff as people are seeking out better care for major surgeries. Everything that I read says that people are holding off a little longer for major surgery if they can due to lack of money and/or loss of insurance.

    I am sure he was asked if the economy is affecting the company, but it almost feels like he's downplaying the economic issues that they are not too real. He should try telling that to the struggling small companies that are trying to raise money to develop and market their innovative products in today's climate. I wonder what they think of his statements.

    I am sure there are a lot of people in this country that are not being hit by this economy or even doing better now, but is it right to announce that the economy is not too bad?

  • Anonymous

    NuVasive is a good company, but they have a very arrogant view of themselves in the marketplace. This is just another example of that.

    If business is going so well for them, I wonder if that means they will finally make a profit or is it about time for another round of PIPE???

  • Anonymous

    Thank Heavens that we have some realistic people on this board. The only thing NuVasive has is XLIF. Outside of that surgical approach, it still consists of me too products. Maybe NuVasive is on the road to recovery because Alex is no longer buying $500 bottles of wine. Not!

  • Anonymous

    And so it goes, Alex is a pompous ass, who eventually will be exposed for what he is. This is only the tip of the iceberg…

  • Musculoskeletal Man

    How is it that a company that generates so much revenue and is backed by the ridiculous Wall Street analysts continues to be unprofitable? Investors should keep buying stock and pumping capital into NuVasive so Alex could keep buying $500 dollar bottles of wine and get fatter.

  • Anonymous

    Thank Heavens that we have some realistic people on this board. The only thing NuVasive has is XLIF. Outside of that surgical approach, it still consists of me too products. Maybe NuVasive is on the road to recovery because Alex is no longer buying $500 bottles of wine. Not!

  • InnocentByStander

    Perhaps the recent 30% hit NUVA took on it’s stock had nothing to do with the economy. Maybe it was just poor leadership…

←
→

© 2013 OrthoSpineNews